OOIR: Observatory of International Research

Papers

(The TQCC of Therapeutic Advances in Hematology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine	33
Monocyte or white blood cell counts and β₂ microglobulin predict the durable efficacy of daratumumab with lenalidomide	33
Prognostic impact of IL7R mutations on acute myeloid leukemia	33
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy	32
BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study	32
Brain iron content and cognitive function in patients with β-thalassemia	27
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria	27
Macrofocal multiple myeloma in the era of novel agents in China	26
A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia	26
Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors	25
Role of abatacept in the prevention of graft-versus-host disease: current perspectives	24
Treatment of multiple myeloma: What is the impact on T-cell function?	24
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes	21
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-cente	21
The role of surveillance computed tomography in patients with follicular lymphoma	20
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China	20
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma	20
Thanks to Reviewers	18
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review	17
How to translate and implement the current science of gene therapy into haemophilia care?	17
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III	17
Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France	15
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging st	15
Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia	14
Advancements in minimal residual disease detection: a practical approach using single-cell droplet PCR for comprehensive monitoring in hematological malignancy	14

Mantle cell lymphoma management trends and novel agents: where are we going?	14
Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report	14
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion	13
Anemia is associated with long-term exposure to PM_2.5 and its components: a large population-based study in Southwest China	13
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis	13
Cardiovascular-specific mortality among multiple myeloma patients: a population-based study	13
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia	12
Non-invasive prenatal testing for fetal Ss, Kidd, and CTL2 blood group prediction by multiplex digital droplet PCR	12
A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma	12
Corrigendum to “Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS”	12
Association of CVAI, LAP and SMI with risk of haematological toxicity after immunochemotherapy in patients with DLBCL: a retrospective study	12
A new beginning: can omidubicel emerge as the next, viable alternative donor source?	11
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysis	11
Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival	11
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors	10
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis	10
Toxicity management strategies for next-generation novel therapeutics in multiple myeloma	10
Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–match	10
Between Charybdis and Scylla—an Odyssey in AL amyloidosis: insights and learnings from a narrative review and case report series	10
Interferons in the treatment of myeloproliferative neoplasms	10
Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia	10
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis	10
Assessment of risk factors for acute graft-versus-host disease post-hematopoietic stem cell transplantation: a retrospective study based on a proportional odds model using a nonlinear mixed-eff	10
Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study	9
Prognostic significance of MRD and its correlation with arsenic concentration in pediatric acute promyelocytic leukemia: a retrospective study by SCCLG-APL group	9
Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study	9
Risk factors and prognosis of thrombocytopenia in people living with HIV/AIDS	8
Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study	8
Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia	8
Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study	8
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study	8
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry	8
Efficacy of therapeutic strategies on thrombocytopenia after hematopoietic stem cell transplantation—an evidence-based meta-analysis	8
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL	8
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma	8
Frontline treatment of IDH1-mutated myelodysplastic syndrome with ivosidenib: clinical cases and therapeutic insights	8
Current state of CAR-T therapy for T-cell malignancies	8
Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study	8